Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
[ad_1] Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases,…
Grünenthal
Continue reading
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
[ad_1] The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery…
Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer
[ad_1] Aachen, Germany, 30 September 2024 – Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and…